High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
Authors:
- Jorge E. CortesJCJorge E. Cortes
- Hagop M. KantarjianHKHagop M. Kantarjian
- Stuart L. GoldbergSGStuart L. Goldberg
- Bayard L. PowellBPBayard L. Powell
- Francis J. GilesFGFrancis J. Giles
- Meir WetzlerMWMeir Wetzler
- Luke AkardLALuke Akard
- John M. BurkeJBJohn M. Burke
- Robert KerrRKRobert Kerr
- Mansoor SalehMSMansoor Saleh
- August SalvadoASAugust Salvado
- Karen McDougallKMKaren McDougall
- 1 October 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (28) , 4754-4759
Abstract
Purpose: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). Patients and Methods: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial therapy in 115 patients (70% Sokal low risk) with newly diagnosed CML in chronic phase who were observed for both molecular and cytogenetic responses for up to 18 months. Eighty-three patients (72%) completed the study, 10 patients (9%) discontinued the study because of adverse events, and six patients (5%) discontinued because of unsatisfactory therapeutic effect. Results: Polymerase chain reaction analysis demonstrated rapid kinetics of major molecular response (MMR), with 48% of patients achieving MMR by 6 months, 54% by 12 months, and 63% by 18 months. Corresponding complete molecular response rates were 39%, 44%, and 55%, respectively. Median dose-intensity was 98%. Overall, 79% of patients who received at least 90% dose-intensity achieved MMR. The most frequent adverse events included myelosuppression, rash, fatigue, and musculoskeletal symptoms. Conclusion: This study suggests that imatinib 400 mg twice a day results in more rapid reduction in tumor burden than imatinib 400 mg/d with minimal added toxicity.Keywords
This publication has 11 references indexed in Scilit:
- Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemiaHaematologica, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemiaBlood, 2004
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaBlood, 2003
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantationBlood, 2001
- Chronic myelogenous leukemia: A reviewThe American Journal of Medicine, 1996